This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vilenchik, M. Articles by Stein, C. A. Search for Related Content PubMed PubMed Citation Articles by Vilenchik, M. Articles by Stein, C. A.

Antisense RNA Down-Regulation of bcl-xL Expression in Prostate Cancer Cells Leads to Diminished Rates of Cellular Proliferation and Resistance to Cytotoxic Chemotherapeutic Agents

Departments of Medicine [A. J. R., L. B., D. S., C. A. S.] and Pharmacology [M. V., C. A. S.], Columbia University, College of Physicians and Surgeons, New York, New York 10032

bcl-xL is a M_r 26,000 bcl-2 homologue that is highly expressed in prostate cancer cells. In previous studies, the down-regulation of its expression by antisense oligonucleotides led to resistance. In this work, the 445-bp 5' terminus of the bcl-xL cDNA was cloned in the antisense orientation and stably transfected into DU145 and LNCaP prostate cancer cells. In the DU145 (and to a lesser extent the LNCaP) transfectants, phenotypic changes (versus mock-transfected cells) included an increase in doubling time (from 36 to 175 h) in the clone in which bcl-xL protein expression was 25% of control. The transfectants did not demonstrate characteristic apoptotic changes, as demonstrated by 4',6-diamidino-2-phenylindole staining, lack of either DNA laddering, caspase-3 activation, or poly(ADP)ribose and lamin cleavage, and the absence of a significant sub-G₀ population. Cell cycle analysis demonstrated an increase in a tetraploid population (from 28% to 66%), as well as the appearance of a hypertetraploid population. Levels of cIAP-1 protein were almost undetectable in the mock cells but increased at least 25-fold in the DU145 transfectants. The down-regulation of bcl-xL in both DU145 (and to a much lesser extent in LNCaP) cells led to their resistance to cytotoxic agents, including docetaxel, mitoxantrone, etoposide, vinblastine, and carboplatin. Reversion of bcl-xL expression in stable DU145 transfectants to nearly the levels found in the mock-transfected cells was accomplished by retroviral infection of the cells with a bcl-xL sense cDNA under control of a prolific promoter. This led to a dramatic increase in the growth rate and in BrdUrd incorporation, as well as a sharp decrease in the expression of cIAP-1 protein. Overall, these findings highlight the adaptability of prostate cancer cells to loss of bcl-xL and suggest that in addition to its prosurvival role, bcl-xL protein may also be involved in the regulation of the rate of cellular proliferation.

This article has been cited by other articles:

				T. Syrovets, J. E. Gschwend, B. Buchele, Y. Laumonnier, W. Zugmaier, F. Genze, and T. Simmet Inhibition of I{kappa}B Kinase Activity by Acetyl-boswellic Acids Promotes Apoptosis in Androgen-independent PC-3 Prostate Cancer Cells in Vitro and in Vivo J. Biol. Chem., February 18, 2005; 280(7): 6170 - 6180. [Abstract] [Full Text] [PDF]

				L. Xu, D. Yang, S. Wang, W. Tang, M. Liu, M. Davis, J. Chen, J. M. Rae, T. Lawrence, and M. E. Lippman (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer Mol. Cancer Ther., February 1, 2005; 4(2): 197 - 205. [Abstract] [Full Text] [PDF]

				B. E. Barton, T. F. Murphy, P. Shu, H. F. Huang, M. Meyenhofen, and A. Barton Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines Mol. Cancer Ther., October 1, 2004; 3(10): 1183 - 1191. [Abstract] [Full Text] [PDF]

				A. W. Tolcher, J. Kuhn, G. Schwartz, A. Patnaik, L. A. Hammond, I. Thompson, H. Fingert, D. Bushnell, S. Malik, J. Kreisberg, et al. A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer Clin. Cancer Res., August 1, 2004; 10(15): 5048 - 5057. [Abstract] [Full Text] [PDF]

				R. Bagheri-Yarmand, A. H. Talukder, R.-A. Wang, R. K. Vadlamudi, and R. Kumar Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis Development, July 15, 2004; 131(14): 3469 - 3479. [Abstract] [Full Text] [PDF]

				A. Raffo, J. C. Lai, C. A. Stein, P. Miller, S. Scaringe, A. Khvorova, and L. Benimetskaya Antisense RNA Down-Regulation of bcl-2 Expression in DU145 Prostate Cancer Cells Does Not Diminish the Cytostatic Effects of G3139 (Oblimersen) Clin. Cancer Res., May 1, 2004; 10(9): 3195 - 3206. [Abstract] [Full Text] [PDF]

				A. P. Singh, N. Moniaux, S. C. Chauhan, J. L. Meza, and S. K. Batra Inhibition of MUC4 Expression Suppresses Pancreatic Tumor Cell Growth and Metastasis Cancer Res., January 15, 2004; 64(2): 622 - 630. [Abstract] [Full Text] [PDF]

				M. Fu, M. Rao, C. Wang, T. Sakamaki, J. Wang, D. Di Vizio, X. Zhang, C. Albanese, S. Balk, C. Chang, et al. Acetylation of Androgen Receptor Enhances Coactivator Binding and Promotes Prostate Cancer Cell Growth Mol. Cell. Biol., December 1, 2003; 23(23): 8563 - 8575. [Abstract] [Full Text] [PDF]

				C. Nakahara, K. Nakamura, N. Yamanaka, E. Baba, M. Wada, H. Matsunaga, H. Noshiro, M. Tanaka, T. Morisaki, and M. Katano Cyclosporin-A Enhances Docetaxel-Induced Apoptosis through Inhibition of Nuclear Factor-{kappa}B Activation in Human Gastric Carcinoma Cells Clin. Cancer Res., November 1, 2003; 9(14): 5409 - 5416. [Abstract] [Full Text] [PDF]

				K. H. Maclean, U. B. Keller, C. Rodriguez-Galindo, J. A. Nilsson, and J. L. Cleveland c-Myc Augments Gamma Irradiation-Induced Apoptosis by Suppressing Bcl-XL Mol. Cell. Biol., October 15, 2003; 23(20): 7256 - 7270. [Abstract] [Full Text] [PDF]

				D. R. Mercatante, J. L. Mohler, and R. Kole Cellular Response to an Antisense-mediated Shift of Bcl-x Pre-mRNA Splicing and Antineoplastic Agents J. Biol. Chem., December 13, 2002; 277(51): 49374 - 49382. [Abstract] [Full Text] [PDF]